Mouse Anti-Human CD120a Antibody (S-4206)

CD120a protein, also known as tumor necrosis factor receptor type 1 (TNF-R1, p55/p60), is a key receptor in the tumor necrosis factor (TNF) signaling pathway. It belongs to the TNF receptor superfamily and is widely expressed on the surface of various nucleated cells. Upon binding to its ligands TNF-α and lymphotoxin-α (LT-α), CD120a recruits multiple adaptor proteins (such as TRADD) through its intracellular death domain (DD), thereby initiating two major downstream signaling pathways: one activates the caspase cascade to induce apoptosis, playing important roles in immune regulation, cellular homeostasis, and anti-tumor immunity; the other activates the NF-κB and MAPK pathways to promote the expression of inflammatory factors, cell survival, and proliferation. This dual “life-or-death” function makes CD120a a central regulatory molecule in inflammation, autoimmune diseases, tumorigenesis, and infectious diseases. For instance, in autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease, its abnormal activation can lead to excessive inflammatory damage. Consequently, biologics targeting the CD120a/TNF-α axis (e.g., infliximab, adalimumab) have become crucial clinical therapies. Additionally, CD120a is involved in systemic inflammatory responses, such as fever and acute-phase reactions, serving as a vital bridge between innate and adaptive immunity.